DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...
The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
Roche is planning to launch the device in select European countries soon. Following the receipt of the FDA letter, DexCom’s share price has been on a declining trend. However, few analysts do ...
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
Woman's World on MSN2d
Struggling With Belly Fat? Over-The-Counter Glucose Monitors Can HelpAny time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...
New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...
News-Medical.Net on MSN5d
Automated insulin delivery systems are safe and effective for older adults with type 1 diabetesNew research from Washington State University in collaboration with five other institutions suggests that automated insulin ...
The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need ... for one two-week sensor and £300 for four. There are more than 25 million ...
Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback